Abstract
Although the contribution of the bone marrow mesenchymal stem cells (BM-MSCs) in cancer progression is emerging, their potential roles in prostate cancer (PCa) remain unclear. Here, we showed that PCa cells could recruit BM-MSCs and consequently the metastatic ability of PCa cells was increased. We also found that the increased metastatic ability of PCa cells could be due to the increased PCa stem cell population. Mechanism dissection studies found that the upregulation of Chemokine ligand 5 (CCL5) expression in BM-MSCs and PCa cells, after MSCs infiltrated into the PCa cells, subsequently downregulated androgen receptor (AR) signaling, which was due to inhibition of AR nuclear translocation. Interruption of such signaling led to suppression of the BM-MSCs-induced PCa stem cell population increase and thereby inhibited the metastatic ability of PCa cells. The PCa stem cell increase then led to the upregulation of matrix metalloproteinase 9, ZEB-1, CD133 and CXCR4 molecules, and enhanced the metastatic ability of PCa cells. Therefore, we conclude that the BM-MSCs-mediated increased metastatic ability of PCa cells can be due to the PCa stem cell increase via alteration of the CCL5–AR signaling pathway. Together, these results uncover the important roles of BM-MSCs as key components in the prostate tumor microenvironment to promote PCa metastasis and may provide a new potential target to suppress PCa metastasis by blocking BM-MSCs infiltration into PCa.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006; 124: 615–629.
Zeng Y, Opeskin K, Goad J, Williams ED . Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 2006; 66: 9566–9575.
Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA 2009; 106: 3414–3419.
Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257–272.
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557–563.
Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med 2011; 208: 2641–2655.
Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852–857.
Park D, Spencer JA, Koh BI, Kobayashi T, Fujisaki J, Clemens TL et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell 2012; 10: 259–272.
Chong JJ, Chandrakanthan V, Xaymardan M, Asli NS, Li J, Ahmed I et al. Adult cardiac-resident MSC-like stem cells with a proepicardial origin. Cell Stem Cell 2011; 9: 527–540.
Lee CH, Shah B, Moioli EK, Mao JJ . CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J Clin Invest 2010; 120: 3340–3349.
Gao Y, Yao A, Zhang W, Lu S, Yu Y, Deng L et al. Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene 2010; 29: 2784–2794.
Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009; 69: 8932–8940.
Loebinger MR, Eddaoudi A, Davies D, Janes SM . Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69: 4134–4142.
Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I . Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 2012; 30: 266–279.
Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M . Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res 2010; 70: 10044–10050.
Jodele S, Chantrain CF, Blavier L, Lutzko C, Crooks GM, Shimada H et al. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res 2005; 65: 3200–3208.
Charoenfuprasert S, Yang YY, Lee YC, Chao KC, Chu PY, Lai CR et al. Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer. Oncogene 2011; 30: 3570–3584.
Rossi DJ, Jamieson CH, Weissman IL . Stems cells and the pathways to aging and cancer. Cell 2008; 132: 681–696.
Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT . CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117 (Pt 16): 3539–3545.
Trerotola M, Rathore S, Goel HL, Li J, Alberti S, Piantelli M et al. CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res 2010; 2: 135–144.
Yu X, Lin Y, Yan X, Tian Q, Li L, Lin EH . CD133, stem cells, and cancer stem cells: myth or reality? Curr Colorectal Cancer Rep 2011; 7: 253–259.
Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012; 31: 1354–1365.
Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012; 31: 4898–4911.
Rybak AP, He L, Kapoor A, Cutz JC, Tang D . Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim Biophys Acta 2011; 1813: 683–694.
Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009; 106: 268–273.
Shi X, Gipp J, Bushman W . Anchorage-independent culture maintains prostate stem cells. Dev Biol 2007; 312: 396–406.
Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012; 481: 85–89.
Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI et al. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 2007; 67: 9199–9206.
Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010; 17: 319–332.
Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004; 6: 459–469.
Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L et al. Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst 2008; 100: 1022–1036.
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer cell 2011; 20: 457–471.
Dayyani F, Gallick GE, Logothetis CJ, Corn PG . Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011; 103: 1665–1675.
Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182–12187.
Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 2008; 105: 12188–12193.
Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP et al. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol 2012; 5: 14–26.
Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC, Chang C . Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl 2007; 9: 181–188.
Huang XP, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisel RD et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010; 122: 2419–2429.
Auletta JJ, Deans RJ, Bartholomew AM . Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 2012; 119: 1801–1809.
Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011; 71: 614–624.
Ye H, Cheng J, Tang Y, Liu Z, Xu C, Liu Y et al. Human bone marrow-derived mesenchymal stem cells produced TGFbeta contributes to progression and metastasis of prostate cancer. Cancer Invest 2012; 30: 513–518.
Delude C . Tumorigenesis: testing ground for cancer stem cells. Nature 2011; 480: S43–S45.
Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 2012; 72: 527–536.
Acknowledgements
We thank Karen Wolf for help with the manuscript preparation. This work was supported by NIH Grants (CA122840 and CA256700), and Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004) to China Medical University, Taiwan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Luo, J., Ok Lee, S., Liang, L. et al. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 33, 2768–2778 (2014). https://doi.org/10.1038/onc.2013.233
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.233
Keywords
This article is cited by
-
Comprehensive Review on the Effect of Stem Cells in Cancer Progression
Current Tissue Microenvironment Reports (2024)
-
Cranial Neural Crest Cells Contribution to Craniofacial Bone Development and Regeneration
Current Osteoporosis Reports (2023)
-
TA-MSCs, TA-MSCs-EVs, MIF: their crosstalk in immunosuppressive tumor microenvironment
Journal of Translational Medicine (2022)
-
Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy
Cell & Bioscience (2021)
-
Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature
Cancer Cell International (2021)